Sarah James: And then in my conversations with the payers, there seems to be some movement going on in the regulatory front in certain Democratic states like California and New York around GLP-1 coverage that could be positive for acquiring coverage. I’m wondering if you’re seeing any of that flow through in your business in volumes in California and New York or if it’s too early.
Justin Schreiber: I think it’s too early. Our patients are still having there’s still issues with coverage for these medications. There’s still supply issues. Patients are oftentimes struggling to find them in neighborhood pharmacies. So, I’m not familiar with those legislative initiatives. But we’re of course all for that at LifeMD. One of the interesting things is we see firsthand all day every day how many people’s lives are being positively impacted by these medications. And I understand it’s all about long-term outcomes. But based on what we’ve been seeing over the last 12 months I find it highly unlikely that we’re not going to see pronounced very positive long-term outcomes from these therapies.
Sarah James: Good. And last question if I could. Can you give us any update on the cross-selling efforts that you guys have going on between the legacy businesses like Shapiro and Rex and your Primary Care? Any update there?
Justin Schreiber: I don’t have any specific numbers that we’re prepared to share today. I can tell you that the weight management offering is the number one service that is cross sold to RexMD patients in their member portal. So, that’s been really successful. And this is something that in 2024 we expect to dramatically accelerate. But I don’t have any specific numbers that I’m prepared to share today Sarah.
Sarah James: Okay. Thank you.
Operator: Our next question comes from Yi Chen with H.C. Wainwright. Please proceed with your question.
Yi Chen: Thank you for taking my questions. So, the weight management revenue more than quadrupled versus the second quarter. Do you think that’s primarily because some of your competitors do not offer this product or because there’s unique combination of offerings that’s available at LifeMD?
Justin Schreiber: There are a lot of other companies telehealth providers offering this product. So, no I don’t think that’s the reason for our success. I think that there’s very, very high demand across the country for these drugs because of their efficacy. And I think that LifeMD one already has a very strong brand out there that people recognize; and I think we’re doing a great job at bringing patients in helping them access amazing care. We’re seeing more and more patients that are coming to us because they heard about LifeMD from a friend or family member that’s on a medication. So, I think it’s an extremely competitive environment out there, but I think we’re doing a great job at doing what we do best.
Yi Chen: Do you believe the weight management revenue has the potential to sequentially grow twice, three times, or four times every quarter going forward?
Marc Benathen: Yes, this is Marc. The weight management revenue has the potential to grow extremely substantially every single quarter going forward for the foreseeable future. Is it going to quadruple every single quarter? No, as the numbers get bigger, obviously, you would end up with a completely insane number. However, I do expect in the next quarter to see in weight management more than 100% sequential growth so the revenue more than doubling quarter on quarter. And I do expect to see very heightened growth next year versus this year. This will all be factored into the guidance that we provide for 2024 in the beginning of 2024. But we don’t see any signs of it slowing down. As a matter of fact the business continues to accelerate.
Yi Chen: And last question. Do you intend to keep WorkSimpli throughout 2024?
Marc Benathen: Yes, this is Marc. We’re evaluating all options for WorkSimpli. We haven’t made any final determinations. If we did exit the business next year, and at some point, we will exit the business we expect it to be a substantial exit returning a significant amount of cash back to the company and obviously, generating a lot of value for our shareholders. Something that we’re exploring, but no final determinations have been made yet but we do expect it to be substantially beneficial to shareholders.
